SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...

Global Vaccine Adjuvants Market size is expected to be worth around USD 1289.0 Million by 2023 from USD 3,933.7 Million in 2032, growing at a CAGR of 13.6% The Research Segment Is The Fastest ...

Additionally, there is the adjuvant QS-21, used in several innovative vaccines against diseases, plus promising new vaccine and immunotherapy treatments in the oncology space. BSI is now using its ...

LEXINGTON, Mass.--(BUSINESS WIRE)--SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the publication of their latest preclinical ...

January 28, 2025 - Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that ...

SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the publication of their latest preclinical data in the journal Vaccines.

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside ... followed by Keytruda and V940 given as adjuvant therapy. Specifically, it will ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...